A Phase II Investigator-Initiated Clinical Trial Evaluating the Efficacy and Safety of Combination Therapy with a PAI-1 Inhibitor (TM5614) and Immune Checkpoint Inhibitor Consolidation Therapy following Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (TM-Alliance study)

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2026
This article has no abstract
Epistemonikos ID: 7ae06d0bbf9509ee90b7583a6ac6a2b15eb94000
First added on: Aug 10, 2026